Lurasidone - real world evidence study in patients with schizophrenia
Research type
Research Study
Full title
An observational, real world evidence study to describe clinical experience with lurasidone in the treatment of adult patients with schizophrenia in routine clinical practice in Europe.
IRAS ID
250852
Contact name
Matthew Sargeant
Contact email
Sponsor organisation
Sunovion Pharmaceuticals
Clinicaltrials.gov Identifier
NA, NA
Duration of Study in the UK
1 years, 2 months, 31 days
Research summary
This is an international, multi-centre observational, real world evidence study. This study will be conducted in 4 to 8 mental health centres in the United Kingdom (UK), Netherlands and Switzerland.
The study is based on both retrospective and prospective collection of data from patients’ medical records. It is a single group study without a comparator, to reflect real world clinical practice. There will be no changes to patient management for the purposes of any part of the study and no additional tests, investigations or visits will be required.
The population for this study is adult patients diagnosed with schizophrenia who received treatment with a medicine called lurasidone as part of their standard clinical care. It is expected to recruit 80 patients in total. The main purpose is to find out more about how lurasidone is used to treat patients with schizophrenia in the real world and how well it works.
REC name
London - Bromley Research Ethics Committee
REC reference
18/LO/1591
Date of REC Opinion
7 Sep 2018
REC opinion
Favourable Opinion